Skip to content
  • Team
  • News
  • Team
  • News
Contact us
Neuropathic Knee Pain

Nervonik Completes First-in-Human Clinical Trial of Nerve Stimulation Technology for Chronic Pain Treatment

Read More »
March 3, 2025

Nervonik receives regulatory approval to start First-in-Human study with Novel Peripheral Nerve Stimulation Technology for Chronic Pain

Read More »
August 8, 2024
Latest Articles
Neuropathic Knee Pain

Nervonik Completes First-in-Human Clinical Trial of Nerve Stimulation Technology for Chronic Pain Treatment

Read More »

Nervonik receives regulatory approval to start First-in-Human study with Novel Peripheral Nerve Stimulation Technology for Chronic Pain

Read More »
Subscribe for Updates

Follow Nervonik’s progress, publications, and company updates.

Follow Us
Linkedin

Contact Us for More

Nervonik technology is under development and is not cleared or approved by the U.S. Food and Drug Administration (FDA). If you are interested in learning more about our team or opportunities for collaboration, reach out using this form and we will respond as soon as possible.

Our mission is to develop an advanced, non-drug neuromodulation option intended to address chronic neuropathic pain.

Regulatory Status: Nervonik technology is under development and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). No Nervonik device is commercially available in the United States.

No Medical Advice: The information on this website is provided for informational purposes only and is not medical advice. Patients should consult a qualified healthcare professional regarding diagnosis and treatment decisions.

Linkedin
Menu
  • Home
  • Team
  • Contact Us
DON’T MISS AN UPDATE

Follow Nervonik’s progress, publications, and company updates.

© 2026 All Rights Reserved.

Privacy Policy    |    Site by Elevantics